Bharat Biotech’s Coronavirus Vaccine Recommended By Expert Panel, Regulator’s Approval Awaited
Mumbai: The Subject Expert Committee (SEC) on Saturday recommended India Biotech’s Coronavirus vaccine (Covaxin) to be allowed “restricted emergency use”. The development came after a government-appointed panel, in the first day, considered the second time India Biotech’s emergency use request.
Also Read: COVID-19 Vaccine Will Be Available In UP Near Makar Sankranti: CM Yogi Adityanath
The panel has submitted its findings to the national regulator- Drugs Controller General of India, which will take a final decision on the case. If all goes well and the vaccine gets final approval, Bharat Biotech’s coronavirus virus can be launched soon for vaccination in the country.
Also Read: India-UK flights To Resume From January 6: Hardeep Singh Puri
The Government of India stated, “The Subject Expert Committee (CDSCO) of the Central Drugs Standard Control Organization (CDSCO) recommends DCGI to allow for limited emergency use of the vaccine for the Serum Institute of India, Pune.” in a statement.
Also Read: COVID-19 Vaccine Will Be Provided Free Of Cost: Health Minister
“CDSCO recommends allowing for restricted use in emergencies in the public interest, particularly in clinical trial mode, especially in the context of mutant strain infection, to Bharat Biotech&for conduct of PhaseIII Clinical Trial Protocol to Cadila.”
https://twitter.com/ANI/status/1345369083282300931?s=20
The Drugs Controller General of India (DCGI) will now take a final decision on the emergency approval of vaccines based on the recommendations of the expert panel.
According to the Union Ministry of Health and Family Welfare, the meeting of the Subject Expert Committee (SEC) of the National Drug Regulator will make appropriate recommendations to DCGI before taking a final decision.
Follow us on Twitter, Instagram, and like us on Facebook for the latest updates and interesting stories.
